[ad_1]
At a time when all vaccines seem to need a booster dose to respond to covid-19 mutations, in Japan scientists are studying a vaccine that will permanently protect us from the disease and provide enough antibodies so so that no booster dose is needed.
Once the researcher in Tokyo Metropolitan Institute, Michinori Kohara, wondered if he could develop a vaccine against the smallpox standards he has worked for for the past three decades. In April 2020, Kohara, together with the National Organization for Infectious Diseases, began research. They chose the non-pathogenic type of the vaccinia virus variant called DIs, which carries the SARS-COV-2 pin gene. Within a week, this vaccine can develop the right antibodies in the body to keep the immune system strong. In fact, experiments on mice yielded very good results.
“I have worked on various vaccine technologies, such as adenovirus and RNA delivered, but the vaccine that uses the vaccinia virus carrier is the most powerful of all with few side effects,” Kohara told The Japan Times in an interview. “The characteristics of this vaccine are that it can form antibodies and perpetual immunity.”
Japanese pharmaceutical company Nobelpharma Co. will conduct the first and second phase of clinical trials of the Kohara vaccine in Japan within the first half of 2023 to 150 to 200 volunteers, including those who have been infected and who have been fully vaccinated. If efficacy and safety are confirmed, the final phase clinical trial will begin shortly thereafter, with the goal of commercializing it by 2024, he says.
One of the biggest obstacles to the vaccine is securing the tens of billions of genes needed to perform the final clinical trial, as Kohara says Nobelpharma cannot fund it itself. Although the government has allocated more than $ 100 billion to fund large-scale clinical trials from local drug manufacturers, there is no plan to subsidize the project’s clinical trials.
top channel
[ad_2]
Source link
